

Chapter 2

Clinical Relevance of Multidrug-Resistance-Proteins (MRPs) for Anticancer Drug Resistance and Prognosis

E.A. Roundhill, J.I. Fletcher, M. Haber, and M.D. Norris

Abstract Chemoresistance in cancer is frequently associated with elevated levels of multidrug transporters. While P-glycoprotein is the best known, the majority of multidrug transporters belong to the Multidrug Resistance Protein (MRP) family, also known as the ABCC family, which includes MRP1–9. These proteins are typically found in the plasma membrane of cells, where they efflux a broad range of both physiological substrates and xenobiotics, including anticancer drugs. Consistent with the removal of chemotherapeutics from the cancer cell, high expression of several MRPs has been linked to poorer outcome in a variety of cancer types, suggesting these proteins represent targets for therapy. In this review we will describe the range of reported substrates for MRP1–9 in vitro, discuss associations between the MRP family and patient outcome, and investigate the evidence that MRP family members contribute directly to drug resistance based on in vivo models and patient data. We will also discuss the value of MRP expression as a prognostic marker and its potential role in selecting treatment protocols and examine existing and novel strategies to target MRPs.

Keywords Cancer • MRP • ABCC • Multidrug resistance • Chemotherapy

Abbreviations

ABC	ATP binding cassette
ABCC	ATP binding cassette sub-family C
ALL	Acute lymphoblastic leukaemia
AML	Acute myeloid leukaemia

E. Roundhill • J. Fletcher • M. Haber (✉) • M. Norris
Lowy Cancer Research Centre, Children's Cancer Institute Australia,
Randwick, NSW 2031, Australia
e-mail: ERoundhill@ccia.unsw.edu.au; JFletcher@ccia.unsw.edu.au;
MHaber@ccia.unsw.edu.au; MNorris@ccia.unsw.edu.au

BCRP/ABCG2	Breast cancer resistance protein
CSC	Cancer stem-like cell
CLL	Chronic lymphoblastic leukaemia
ESCC	Esophageal squamous cell carcinoma
EFS	Event-free survival
ESFT	Ewing's sarcoma family of tumours
GSH	Glutathione
HER2	Human epidermal growth factor receptor 2
MDR	Multi-drug resistance
miRNA	MicroRNA
MRP	Multidrug resistance protein
NSCLC	Non-small cell lung cancer
OS	Overall survival
P-gp	P-glycoprotein
RNAi	RNA interference
SCLC	Small cell lung cancer
shRNA	Short hairpin RNA
siRNA	Small interfering RNA
SNPs	Single nucleotide polymorphisms

2.1 Introduction

The net uptake of drugs into cells is regulated by both import and export mechanisms, with the latter commonly mediated by ABC transporters. Not surprisingly, elevated levels of ABC transporters are frequently observed in cancer cells compared to their normal counterparts and the role of ABC transporters in chemoresistance has been an area of major research interest more than three decades. P-glycoprotein (P-gp, MDR1, ABCB1) stands out for conferring the most extensive resistance to the broadest range of compounds [152] and has received by far the most attention, followed by the Breast Cancer Resistance Protein (BCRP, ABCG2). However, at least a dozen other family members have been demonstrated to efflux chemotherapeutics and mediate chemoresistance *in vitro*, the majority of which belong to the ABCC subfamily, commonly referred to as the Multidrug Resistance Protein (MRP) family. For the majority of MRP family members, the ability to confer drug resistance *in vitro* is well established, and a large number of reports describe associations between their expression in tumours and patient outcome. To date, however, compelling evidence for a clinically relevant role in multidrug resistance is very limited. This chapter will examine the ability of MRPs to efflux chemotherapeutics *in vitro*, the available evidence for their importance in clinical drug resistance and mediating therapeutic responses, their potential prognostic value, and possible approaches to more clearly define their roles.

2.2 The ABCC/MRP Subfamily

The ABCC (or MRP) subfamily of ABC transporters consists of 12 members, 9 of which function as energy-dependent transporters, including MRP1–6 (ABCC1–6) and MRP7–9 (ABCC10–12). The remaining members of the ABCC subfamily, CFTR (ABCC7), SUR1 (ABCC8) and SUR2 (ABCC9), are either ion channels or ion channel regulators. The MRPs are often further subdivided into the short MRPs (MRP4, MRP5, MRP8, MRP9), which contain two membrane-spanning domains and two nucleotide binding domains, and the long MRPs (MRP1, MRP2, MRP3, MRP6, MRP7), which contain an additional *N*-terminal membrane-spanning domain. The long MRPs are mostly closely related to MRP1, with 46, 56 and 45 % identity for MRP2, MRP3 and MRP6, respectively, although the identity of MRP7 to long and short MRPs is comparable [35, 142]. The short MRPs are also generally more closely related, with MRP5 and MRP8 exhibiting 42 and 46 % identity with MRP9, while MRP4 is less closely related (31 %) [142]. For more detailed discussion of the structure and evolutionary relationships between family members, the reader is referred to previous comprehensive reviews [33, 35, 142]. Of the MRPs, all except MRP9 [118] have been shown to efflux chemotherapeutics and, therefore, have the potential to contribute to drug resistance in cancer. Drugs established as MRP substrates are listed in Table 2.1. As with P-gp and ABCG2, transporters of the MRP family are also present in a range of pharmacological barriers including in the gastrointestinal tract, the blood–brain barrier and the proximal tubules of the kidney where they contribute to the vectorial transport of their substrates [153]. Consequently, they are key contributors to the absorption, distribution and elimination of cancer drugs. Table 2.2 lists the localisation of MRP family members in different pharmacological barriers and cell types.

2.3 Specificity of MRPs for Chemotherapeutic Agents

A variety of compounds with differing mechanisms of action have been identified as MRP substrates (Table 2.1), ranging from traditional DNA damaging cytotoxics (doxorubicin) to antifolates (methotrexate) and microtubule damaging agents (vin-cristine). In contrast to P-gp, which effluxes unmodified neutral and positively charged hydrophobic drugs, members of the MRP family also efflux a range organic anions and drugs modified by Phase II metabolism, including glutathione (GSH), glucuro-nide and sulphate conjugates, or (in the case of MRP1) efflux some drugs in a GSH-dependent manner. There is significant overlap in the substrate profiles of the family members, particularly within the long and short MRP subfamilies. Each of the long MRPs, for instance, effluxes etoposide (Table 2.1), while each of the short MRPs effluxes nucleoside analogues. Interestingly, MRP7, which has comparable sequence identity to both short and long MRPs, effluxes both these drug classes.

To date there are few examples of targeted agents as substrates of MRP family members. Sorafenib was shown to be an MRP2 substrate [141] while sunitinib has

Table 2.1 Anticancer substrates of MRP1–9

	Class	Drug	Experimental method	References
MRP1	Alkylating agents	Chlorambucil (GSH conjugate)	Stable transfectant	[5, 104]
		Melphalan (GSH conjugate)	Membrane vesicles	[5, 69]
	Anthracenedione	Mitoxantrone	Drug-resistant cell line	[14, 105, 143]
			Membrane vesicles	
			Stable transfectant	
	Anthracyclines	Daunorubicin (GSH conjugate)	Drug-resistant cell line	[14, 27, 128, 126]
			Knockout cell line	
			Stable transfectant	
		Doxorubicin (GSH conjugate)	Drug-resistant cell line	[14, 27, 52, 128, 126]
			Knockout cell line	
			Stable transfectant	
		Epirubicin	Stable transfectant	[27]
	Antifolates	Methotrexate	Membrane vesicles	[61]
			Stable transfectant	
		ZD1694	Stable transfectant	[61]
	Arsenic-based	Arsenate (conversion to arsenite)	Stable transfectant	[27, 93, 128]
			Knockout cell line	
		Arsenite (GSH conjugate)	Knockout cell line	[27, 93, 128]
			Stable transfectant	
	Epipodophyllotoxins	Etoposide (glucuronide conjugate; stimulated by GSH)	Drug-resistant cell line	[14, 27, 52, 128, 69, 133]
			Membrane vesicles	
			Knockout cell line	
			Stable transfectant	
		Teniposide	Knockout cell line	[128]
	Camptothecins	Irinotecan	Drug-selected cells	[23, 150]
		SN-38	Drug-selected cells	[23, 150]
			Membrane vesicles	
	Microtubule damaging	Colchicine	Drug-selected cells	[27, 75, 78]
			Stable transfectant	
	Taxane	Taxol	Stable transfectant	[27]
	Vinca alkaloids	Vinblastine	Drug-resistant cell line	[14, 27, 52]
			Stable transfectant	
		Vincristine (GSH co-transport)	Drug-resistant cell line	[14, 27, 52, 99, 128]
			Knockout cell line	
			Stable transfectant	

(continued)

Table 2.1 (continued)

	Class	Drug	Experimental method	References
MRP2	Anthracyclines	Doxorubicin	Stable transfectant	[31, 77]
		Epirubicin	Stable transfectant	[31]
	Antifolates	GW1843	Stable transfectant	[61]
		Methotrexate	Membrane vesicles	[4, 61]
			Stable transfectant	
		ZD1694	Stable transfectant	[61]
	Arsenic oxoanion	Arsenite	Stable transfectant	[37, 93]
	Camptothecins	Irinotecan	Animal studies	[22]
		SN-38	Animal studies	[22]
	Epipodophyllotoxins	Etoposide (stimulated by GSH)	Stable transfectant	[31]
	Platinum-containing	Cisplatin (GSH dependent)	Stable transfectant	[31, 77]
	Taxanes	Docetaxel	Stable transfectant	[67]
		Paclitaxel	Stable transfectant	[67]
Vinca alkaloid	Vinblastine (stimulated by GSH)	Stable transfectant	[42, 158]	
	Vincristine (stimulated by GSH)	Stable transfectant	[31, 77]	
MRP3	Antifolates	Methotrexate	Stable transfectant	[81]
	Epipodophyllotoxins	Etoposide	Membrane vesicles	[81, 173]
			Stable transfectant	
		Teniposide	Stable transfectant	[81]
	Vinca alkaloid	Vincristine	Stable transfectant	[175]
MRP4	Alkylating agent	Cyclophosphamide	Stable transfectant	[156]
	Camptothecins	10-hydroxy-camptothecin	Stable transfectant	[156]
		Irinotecan	Stable transfectant	[114, 156]
		Rubitecan	Stable transfectant	[156]
		SN-38	Stable transfectant	[114, 156]
	Purine analogues	6-mercaptopurine, Azathioprine	Stable transfectant	[20]
		6-thioguanine	Stable transfectant	[20]
		Methotrexate	Stable transfectant	[89, 156]
MRP5	Anthracyclines	Doxorubicin	Stable transfectant	[125]
	Antifolates	Methotrexate	Membrane vesicles	[125, 165]
			Stable transfectant	
		Pemetrexed	Stable transfectant	[125]
	Platinum-based	Cisplatin	Stable transfectant	[125]
		Oxaliplatin	Stable transfectant	[125]
	Purine analogues	5-fluorouracil, 5'-deoxy-5'-fluoridine	Membrane vesicles	[125]
			Stable transfectant	
		Azathioprine, 6-mercaptopurine	Stable transfectant	[168]
		6-thioguanine	Stable transfectant	[125, 168]

(continued)

Table 2.1 (continued)

	Class	Drug	Experimental method	References
MRP6	Actinomycines	Actinomycin D	Stable transfectant	[9]
	Anthracyclines	Daunorubicin	Stable transfectant	[9]
		Doxorubicin	Stable transfectant	[9]
	Epipodophyllotoxins	Etoposide	Stable transfectant	[9]
		Teniposide	Stable transfectant	[9]
	Platinum-containing	Cisplatin	Stable transfectant	[9]
MRP7	Anthracyclines	Daunorubicin	Stable transfectant	[63]
	Camptothecins	SN-38	Stable transfectant	[63]
	Epipodophyllotoxins	Etoposide	Stable transfectant	[63]
	Epothilones	Epothilone B	Stable transfectant	[63]
	Platinum-containing	Cisplatin	Stable transfectant	[151]
	Pyrimidine analogues	Cytarabine	Animal studies	[62, 63]
			Stable transfectant	
		Gemcitabine	Stable transfectant	[63]
	Taxanes	Docetaxel	Stable transfectant	[62, 63]
		Paclitaxel	Stable transfectant	[62, 63]
	Vinca alkaloids	Vincristine	Stable transfectant	[62, 63]
		Vinblastine	Stable transfectant	[62]
		Vinorelbine	Drug selected cells	[13]
MRP8	Antifolates	Methotrexate	Stable transfectant	[21]
	Purine analogues	5-fluorouracil	Stable transfectant	[53]

Stable transfectant: cells transfected with vector containing specific MRP construct, resulting in specific overexpression of the MRP

Membrane vesicles: inside out membrane vesicles prepared from cell lines, with uptake of substrates into vesicles determined

Drug-resistant cell line: cell line selected for high transporter expression in vitro by continuous culture in the presence of a cytotoxic agent

Knockout cell line: cells derived from knockout mice lacking a particular transporter, or cells expressing an RNAi construct targeting a transporter

Animal studies: studies performed in whole animals

been identified as a weak substrate of MRP4 [66]. However, since a range of tyrosine kinase inhibitors has been identified as MRP inhibitors, including imatinib, nilotinib and cediranib (MRP1 inhibitors [38, 58, 155]) and lapatanib, erlotinib and masatinib (MRP7 inhibitors [72, 85]), it remains possible that some of these agents may be MRP substrates.

While the list of established substrates for MRP family members is quite extensive, it should be recognised that the majority of these were determined to be substrates using cell lines selected for high transporter expression in vitro by continuously culturing in the presence of a cytotoxic drug, cell lines overexpressing individual transporters or as “inside-out vesicles” derived from these cell lines [50]. These systems, while often well controlled, do not necessarily reflect typical endogenous transporter expression levels. Furthermore, transport of a substrate in vitro does not necessarily imply physiological relevance in vivo, with the latter dependent on both the affinity of the substrate for the transporter and the achievable concentration of the substrate

Table 2.2 Localisation of MRP family members relevant to drug disposition

	Pharmacological barrier/cell	Cellular localization	References
MRP1	Blood–brain barrier	Apical (luminal)	[149, 177]
	Blood–cerebrospinal fluid barrier	Basolateral	[127]
	Blood–testis barrier	Basolateral	[157]
	Placenta	Apical	[146]
	Bronchial epithelium	Basolateral	[137]
MRP2	Intestinal epithelium	Apical (luminal)	[48]
	Hepatocytes	Apical (canalicular)	[15, 122]
	Kidney proximal tubules	Apical (luminal)	[136]
MRP3	Intestinal epithelium	Basolateral	[138]
	Hepatocytes	Basolateral (sinusoidal)	[79]
MRP4	Hepatocytes	Basolateral (sinusoidal)	[129]
	Blood–brain barrier	Apical (luminal)	[90, 109, 177]
	Blood–cerebrospinal fluid barrier	Basolateral	[90]
	Kidney proximal tubules	Apical (luminal)	[159]
MRP5	Blood–brain barrier	Apical (luminal)	[109, 177]
MRP6	Hepatocytes	Basolateral (sinusoidal)	[102]
	Kidney proximal tubules	Basolateral	[51, 139]

in vivo. Furthermore, the transport of some substrates is dependent on or modulated by endogenous molecules, as exemplified by the glutathione dependence of both doxorubicin and vincristine transport by MRP1 [14, 27, 52, 128, 99] (Table 2.1). Validation of drugs as transporter substrates using MRP knockout mice has the potential to be informative, although care is required with the interpretation of these data as the affinity of some MRP substrates varies markedly between the mouse and human transporters. Human MRP1, for example, confers resistance to anthracyclines, whereas mouse MRP1 does not [147], while cGMP has a very low affinity for mouse MRP4 compared to human MRP4 [32]. On the other hand, *Mrp1^{-/-}* mice show increased sensitivity to etoposide [100, 166], *Mrp2^{-/-}* mice show elevated plasma methotrexate, *Mrp4^{-/-}* mice have higher levels of plasma and cerebrospinal fluid topotecan [90] and *Mrp7^{-/-}* mice are more sensitive to paclitaxel [64], these findings validated these drugs as physiologically relevant substrates of their respective transporters.

2.4 Association of MRPs With Cancer Survival

2.4.1 MRP1

MRP1 was the first of the family to be identified [26] and as a result, it has been the focus of the majority of clinical and in vitro studies. MRP1 expression has been reported in a variety of cancer types, including chronic lymphoblastic leukaemia (CLL) [111], non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [12], prostate cancer [160], gastric carcinoma [41], esophageal squamous cell

carcinoma (ESCC) [112], colorectal cancer [46], endometrial carcinoma [82], glioma [1], retinoblastoma [19], acute myeloid leukaemia (AML) [91], acute lymphoblastic leukaemia (ALL) [7], breast cancer [44], Ewing's Sarcoma Family of Tumours (ESFT) [131] and neuroblastoma [55, 113]. The presence of MRP1 in this broad range of adult and childhood cancer tissues is consistent with the hypothesis that MRP1 may have an important role in cancer biology. Supporting this, MRP1 expression has been associated with the time to a first event (event-free survival, EFS) and overall survival (OS). More specifically, MRP1 mRNA expression has been linked with poor survival rates in NSCLC [95, 96], neuroblastoma [55, 113], childhood and adult AML [134] and ALL [40, 124]. Similarly, protein expression of this ABC transporter has been linked with an adverse outcome in both adult breast cancer [44] and nasopharyngeal carcinoma [87] and childhood cancers (ESFT; [131]). In contrast, although expressed, MRP1 protein levels have been reported as showing no association with EFS in breast cancer [17], ovarian carcinomas [68] and ALL [148] or OS in AML [43].

Consistent with increased ABC transporter protein expression as a mechanism by which cells develop multidrug resistance, MRP1 mRNA and protein expression have been identified as increased in post-treatment and metastatic samples compared to normal and diagnosis tissues, respectively, in a variety of solid tumours [1, 19, 80]. Similarly, MRP1 expression has been linked with adverse tumour grade in primary epithelial ovarian carcinoma [3]. Taken together, these data suggest a role for MRP1 in the progression of cells from a normal to a malignant phenotype. However, despite this, very few studies have described a significant link between MRP1 expression and patient response to therapy [12, 65, 68, 119], although this likely reflects the complexity of the chemotherapeutic response in patients.

2.4.2 MRP2

Similar to studies investigating MRP1, both MRP2 protein and mRNA expression have been reported as predictive of a worse OS in oesophageal squamous cell carcinoma [172], gall bladder carcinoma [74], breast cancer [101], NSCLC [45], AML [145], and adult and child ALL [124]. An association with a shorter EFS in breast cancer [101] and both adult and child ALL [124] has also been reported. Furthermore, MRP2 also appears to be involved in the response of cells to therapy. For example, in oesophageal squamous cell carcinoma tumour samples, MRP2 mRNA and protein expressions were increased after treatment with MRP2 substrates [172].

2.4.3 MRP3

Unlike MRP1 and MRP2, the prognostic significance of MRP3 expression at the protein level is yet to be evaluated. However, increased mRNA expression levels have been linked to a poor OS and EFS in ALL [124, 145], AML [145] and

pancreatic carcinoma [80]. In contrast, high MRP3 mRNA has been correlated with better outcome in neuroblastoma [59].

2.4.4 MRP4

Although MRP4 expression in cancer has been described [124, 145], studies investigating the clinical relevance of MRP4 are limited and inconsistent. Although a correlation between high MRP4 expression and poor patient survival has been described in epithelial ovarian carcinoma [3] and neuroblastoma [114], low MRP4 protein expression in prostate cancer was linked to a worse EFS and prostate-specific Gleason score [103]. Interestingly, MRP4 expression has been shown to be significantly higher in colorectal and pancreatic carcinoma tumour specimens compared with normal tissue [60], and in polyps from *ApcMin/+* mice compared with normal mucosa [60, 80], consistent with a role in tumour development. Furthermore, *Abcc4* deficiency reduces systemic exposure to oral Dasatinib [49], possibly through reducing oral absorption.

2.4.5 MRP5

A correlation between MRP5 mRNA expression and both overall and EFS has been described in adult and child ALL [124] and, consistent with a causative role in cancer development, mRNA is increased in pancreatic carcinoma compared to normal tissue [80] and in lung cancer patients exposed to platinum drugs [117]. However, no association between MRP5 mRNA levels and patient survival was described in AML [145], suggesting the role of MRP5 is not consistent across all cancer types.

2.4.6 MRP6

To our knowledge only one study has evaluated MRP6 expression in cancer tissues; MRP6 mRNA was expressed in 98 % of ALL patients and was predictive of EFS and OS in both adult and child ALL [124], suggesting a role in the biology of ALL. However, since MRP6 overexpression induced only low-level resistance to chemotherapeutics in vitro (less than threefold increase in IC₅₀ [9]), its ability to contribute to chemoresistance in vivo would seem limited.

2.4.7 MRP7

Although MRP7 has been well characterised in vitro (Table 2.1; [62, 63]), the prognostic significance of this protein is yet to be investigated. However, incubation with MRP7 substrates increased expression of the transporter in NSCLC [13] and in

salivary gland adenocarcinoma [106] cell lines, and MRP7 expression was inversely correlated with paclitaxel sensitivity in 17 non-small cell lung cancer (NSCLC) cell lines [117], suggesting MRP7 is important for the response of cells to specific substrates in cancer.

2.4.8 *MRP8*

The prognostic significance of MRP8 has been examined exclusively in breast cancer and the data are conflicting. Although MRP8 has been associated with a poor prognosis in all subtypes except luminal A [171], mRNA and protein expression were decreased in cancer compared to normal breast tissue [144]. In addition, SNPs within MRP8 have also been linked with cancer risk in 270 Japanese patients [120] but this association was not observed in European cohorts [8, 86]. Therefore, it is likely that MRP8 is similar to MRP3 and MRP6, since despite an association with patient survival in some cases, there is no clear evidence that MRP8 has a specific role in cancer development or the response of cancer cells to therapy.

2.5 Validation of Multidrug Resistance Proteins as Therapeutic Targets

Despite the multitude of clinical correlations between the expression of MRP family members and outcome, evidence of a causative link between MRP expression and clinical multidrug resistance is largely absent. A number of factors contribute to the difficulty of establishing causality subsequent to validation as a therapeutic target. Firstly, drug resistance in the clinic is frequently multifactorial. In addition to enhanced drug efflux, which may be mediated by multiple transporters, alterations in the ability of cancer cells to take up drugs, and alterations affecting the ability of drugs to kill cells, including increased drug metabolism activity, increased DNA repair capacity, alterations to the cell cycle, and increased resistance to apoptosis, can all contribute to multidrug resistance. Secondly, many of the clinical correlations described above have been determined in the context of combination chemotherapy that may include both substrates and non-substrates for a given transporter. Thirdly, the cohorts examined frequently contain multiple cancer subtypes and/or consist of patients treated under differing chemotherapeutic protocols, and have been conducted retrospectively rather than prospectively, or have been conducted solely with diagnosis samples with no measure of MRP expression at relapse. Finally, few if any of the studies described above have been able to account for the possibility of tumour heterogeneity, which may limit the ability to detect MRP expression in the tumour cell subpopulations that allow relapse [148]. This consideration is also relevant for cancer stem-like cell (CSC) populations, which express a variety of ABC transporters [34, 73, 178, 135], that may allow them to remain viable after therapy, leading to re-population of the tumour and patient relapse.

In the absence of compelling clinical data, the knockout of MRPs in genetically modified mouse cancer models can provide opportunities to formally assess their role in drug resistance. Mice deficient in MRP1 [100, 167], MRP2 [24, 108, 161], MRP3 [10, 174], MRP4 [11, 90, 98], MRP5 [32], MRP6 [51, 76] and MRP7 [64] have all been previously described, however to date, only the MRP1 knockout mouse has been crossed to a genetic cancer mouse model. In these experiments, the TH-MYC mouse, a clinically relevant model of the paediatric solid tumour neuroblastoma [164] was crossed with an *Mrp1* knockout (*Mrp1*^{-/-}) mouse [18]. To examine tumour intrinsic effects, as opposed to pharmacokinetic effects, tumours were harvested from *Mrp1*^{+/+} or *Mrp1*^{-/-} mice and engrafted into secondary recipients. In tumours lacking *Mrp1*, the response to the MRP1 substrates vincristine and etoposide was significantly enhanced, with a two to threefold delay in tumour growth, while response to cisplatin and cyclophosphamide, neither of which are effluxed by MRP1, was unaffected by MRP1 status [18]. These data provide direct evidence that MRP1 mediates chemoresistance in vivo. Comparable approaches may be of value for determining the role of other MRPs in chemoresistance, although as mentioned in Sect. 2.3 above, the affinity of some MRP substrates varies markedly between the mouse and human transporters, limiting the ability to extrapolate to humans.

2.6 Can Knowledge of MRP Expression Improve Patient Outcome?

2.6.1 MRP Expression as a Marker of Patient Prognosis

While MRP expression in tumours is frequently associated with outcome, it is less clear whether their expression has additional prognostic value beyond standard predictors of outcome. In breast cancer and ovarian cancer, where histological subtypes are more clearly defined, MRP expression appears to correlate with a more aggressive phenotype. MRP1 was more frequently expressed in both high-risk resistant triple-negative (Human Epidermal Growth Factor Receptor 2 (HER2), oestrogen and progesterone receptor negative) breast cancer [171] and stage 1C endometrial carcinoma [82] than in other subtypes. Furthermore, expression of MRP1 predicted a worse OS in these groups [82, 171], consistent with the classical markers of adverse prognosis in these subtypes [30, 36]. Similarly, MRP8 was more common in HER2 enriched and luminal A subtypes, where it predicts an adverse outcome [171], consistent with the poor survival associated with these patient groups [57]. Furthermore, increased MRP2 mRNA expression has been linked with poor survival in oestrogen receptor negative patients [101] which is linked to an adverse survival compared to receptor positive patients [39]. Therefore, since increased MRP expression identifies a similar population to that of the current well-established markers of patient outcome in breast and ovarian cancer, a role for MRP expression in improving patient prognosis in this scenario is unclear. However, more generally, while associations between MRP expression and clinical outcome have been frequently described, only relatively few studies have addressed whether MRP




Fig. 2.1 Prognostic significance of ABCC gene expression in neuroblastoma. (a) Combined expression of the ABCC1, ABCC3 and ABCC4 genes and cumulative event-free survival (EFS) in 209 patients with neuroblastoma. Patients were categorized into eight clusters on the basis of their combined ABCC1, ABCC3, and ABCC4 expression pattern. Kaplan–Meier survival analysis of these clusters revealed three statistically distinct groupings (Groups A, B, and C), which were associated with the risk of relapse associated with individual ABCC gene expression. Group A

expression is informative independent of established predictors of outcome [3, 87, 95, 114, 134]. The prognostic value of the MRP family, therefore, remains to be firmly established in any cancer, at least at the level of a single gene. It is possible, however, that the combined expression of several MRPs may be of prognostic value. The combined expression of MRP1 (ABCC1), MRP3 (ABCC3), and MRP4 (ABCC4) stratified neuroblastoma patients into groups having excellent, intermediate, or poor outcome (Fig. 2.1), and is one of the most powerful independent prognostic markers yet identified for this disease [59].

2.6.2 *MRP Expression as a Method to Stratify Patients for Therapy*

If we assume that an MRP family member contributes to response to therapy, expression of that MRP might be exploited to select more effective therapeutic options. For instance, patients with high expression of MRP may be treated with a non-MRP substrate chemotherapeutic, thereby avoiding the resistance generated by efflux of the agent.

In addition to expression at the protein and mRNA levels, specific single nucleotide polymorphisms (SNPs) in genes of the MRP family (particularly MRP1) have also been associated with patient survival [2, 16, 154, 121] and response to therapy [154, 163], including alterations in drug plasma levels [2], response to exogenous and endogenous substrates [28, 29, 94, 84], and increased chemotherapy-induced side effects (cardiotoxicity) [84, 140, 169, 162]. Therefore, similar to the basic expression of MRPs in cancer, it would be advantageous to stratify patients with a SNP conferring a more aggressive phenotype, to more extensive therapy, and/or include those substrates unaffected by the expression of a specific SNP. However, as we have described, the response of cells to chemotherapy is dependent on multiple factors and so it is unlikely that the use of a non-MRP substrate in patient treatment would completely bypass the resistance of tumours to therapy.

←
Fig. 2.1 (continued) included only those patients whose tumours displayed low levels of ABCC1 and ABCC4 and high levels of ABCC3, reflecting “favourable” ABCC gene expression. Group B consisted of patients whose tumours displayed only one unfavourable risk factor with respect to the three ABCC genes analysed (i.e., ABCC1 high, ABCC4 high, or ABCC3 low), and Group C comprised patients whose tumours exhibited two or more unfavourable ABCC risk factors. Similar associations between combined ABCC gene expression and increasingly poor outcome were also observed in subgroups of patients (b) with stage 3 or 4 disease or (c) whose tumours lacked MYCN amplification. (d) Combined expression of the ABCC1, ABCC3, and ABCC4 genes and cumulative EFS in 251 neuroblastoma patient samples analysed by Oberthuer et al. [116]. Patients in the Oberthuer et al. cohort were categorized into eight groups as described for panel (a) above. These groupings were also strongly predictive of EFS in subgroups of patients (e) with unfavourable (stages 3 and 4) disease or (f) with non-MYCN-amplified disease. At 0, 3, and 6 years from diagnosis [Panels (a), (b), and (c)], or 0, 5, and 10 years from diagnosis [Panels (d), (e), and (f)], the number of patients at risk of relapse are shown. Figure reproduced from [59], with permission

2.7 MRPs as Targets for Therapy

2.7.1 *Small Molecule Modulators*

Assuming that MRP transporters contribute significantly to clinical multidrug resistance, it will be critical to establish whether MRPs can be successfully targeted to either reverse drug resistance, or at least allow a broader therapeutic window for drugs that are at or approaching their maximum tolerated dose. Therefore, a variety of strategies have been employed to abolish the resistance caused by MRPs. The most common of these is the use of small molecule inhibitors which, prevent binding or efflux of substrates, thus enhancing the efficacy of chemotherapeutics [152]. Although many small molecule inhibitors of MRPs have been evaluated in vitro and shown good inhibition of efflux activity and enhanced the effects of MRP substrates (Table 2.1), sulindac, an inhibitor of MRP1 ([115], clinicaltrials.gov) is the only modulator to progress through in vivo studies to clinical trials. Several hypotheses have been suggested as to why a lack of correlation exists between the responses observed using in vivo models and behaviour in clinical studies, including differences in pharmacokinetics of combination therapies in mice and humans, leading to unpredicted toxicities. Furthermore, the cellular heterogeneity that exists in patient tumours, in addition to differences in basal MRP expression and pharmacokinetic activity, cannot be modelled effectively using in vitro cell line and in vivo mouse models.

Inhibitors of P-glycoprotein (discussed in detail elsewhere in this volume) have been extensively examined in clinical studies and several P-gp inhibitors, also reported to inhibit MRP1, have been evaluated in Phase I clinical trials [123, 132]. However, only one MRP inhibitor, sulindac, has been examined in a Phase II clinical trial, given in combination with epirubicin in patients with advanced melanoma, where no unacceptable toxicity was observed (ClinicalTrials.gov). Despite the limited MRP inhibitor trials, extensive studies modulating P-gp have identified a range of challenges associated with ABC transporter protein inhibition. For instance, pharmacokinetic interactions between modulators and chemotherapeutics often limit the normal efflux, absorption and metabolism of therapeutics, leading to unacceptable plasma levels. Therefore, it is essential to appreciate the normal physiological role of these proteins when developing inhibitors.

An ideal modulator would have high specificity and potency, good bioavailability, absence of toxicity in combination with chemotherapeutics and be screened/ designed specifically for MRP inhibition. As with early generation P-gp inhibitors, MRP inhibitors have typically been drugs previously identified for other purposes. Sulindac, for example, is a non-steroidal anti-inflammatory drug [115], while MK-571 was developed as a cysteinyl leukotriene receptor antagonist [92]. Modulators optimised specifically for MRP inhibition would be expected to be more effective. In addition to non-specific modulators, the only clinical trial evaluating sulindac enrolled advanced cancer patients, after failure of initial chemotherapy protocols [115]. As a result, tumours in this cohort may have acquired multiple alternative

mechanisms of resistance, which may also contribute to clinical outcome. Ideally, clinical studies with more stringent criteria and objectives should be employed, including evaluating modulators in ABC transporter expressing cancer types at diagnosis, using MRP substrate chemotherapeutics, effective monitoring of patient side effects/toxicity and effect on MDR phenotype [152].

2.7.2 *Monoclonal Antibodies*

In addition to the traditional inhibition of MRP efflux activity by small molecule modulators, several strategies to prevent MRP activity are currently under investigation. Targeting general cancer cell-specific mechanisms using monoclonal antibodies has been a successful strategy in a variety of leukaemias and solid tumours [88]. However, although a large number of MRP antibodies are currently available and have shown activity in vitro, an antibody targeting an MRP is yet to be evaluated in vivo. In the case of MRP1, in addition to ineffective inhibition, the lack of progression to in vivo studies has also been linked with the intracellular binding of currently available antibodies and subsequent inability to generate antibodies to the extracellular domains [25].

2.7.3 *RNA Interference*

Although RNA interference (RNAi) targeting MRPs has proved valuable in vitro, there are limited studies investigating the use of RNAi in vivo. Significant alterations in tumour mass or substrate accumulation after treatment with substrates and MRP1 siRNA [170] or MRP2 shRNA by adenovirus [107] in vivo have been described, suggesting this is a plausible strategy for MRP inhibition. In addition, several microRNAs have been associated with expression of MRPs, particularly MRP1 in vitro [54, 83, 97]. However, as a single miRNA has multiple mRNA targets [6], it is likely that the addition of an MRP inhibitory miRNA to a cell will induce effects on additional mRNA species and pathways. Therefore, to confirm inhibition of MRP by a particular RNA species as a viable strategy, more extensive validation in vivo is required.

It must be remembered that MRPs are also expressed on the surface of non-cancer cells and so targeting the malignant cell specifically by RNAi represents a challenge. However, recent studies have suggested the use of bio-nanocapsules, which display a molecule capable of recognising a tumour cell-specific target, such as HER2 in breast and ovarian cancer. Consequently, capsules deliver RNAi only to abnormal cells, inducing target protein knockdown [110].

2.8 Are There Roles for MRPs in Cancer Progression Other Than in Drug Resistance?

Although the focus of most studies has been the role of MRPs in drug resistance and the subsequent effects on cancer patient prognosis, there is some suggestion that MRPs may influence patient outcomes by alternative mechanisms [47]. The efflux of endogenous substrates, such as glutathione and sulphur conjugates [56, 176], leukotriene C₄ [92], bilirubin, bile salts [70], 17-beta-D-glucuronide, cAMP and cGMP [20, 71] by MRPs is well described and the ability of cells to successfully maintain cellular homeostasis in conditions of stress, such as chemotherapy insult, may also represent a targetable mechanism. Furthermore, MRPs have also been linked with normal [130] and cancer [59] cell migration *in vitro* and also tumour formation in a transgenic mouse model of neuroblastoma [59], suggesting a possible secondary role for these proteins in cancer development in addition to traditional efflux activity.

2.9 Summary

In this chapter we have described the wide range of known anticancer substrates of MRPs, and the correlations between expression and patient outcome in a variety of cancer types. However, whether these associations will improve the prediction of patient prognosis above existing markers is yet to be fully examined. Furthermore, there is some difficulty in confirming a causative role for MRPs in cancer, since although some substrates induce expression of MRPs in tissues, multiple factors contribute to drug resistance. In addition, clinical correlative studies routinely involve patients who have been treated with differing chemotherapeutic protocols, both between and within a cancer type. A better understanding of the role of MRPs in patient outcome may lead to expression of MRPs being usefully employed to stratify patients with increased expression for more intensive therapy or treatment with a non-MRP substrate. However, only one MRP inhibitor has been evaluated in clinical trials, although monoclonal antibodies and RNAi techniques are currently showing promise as novel strategies for MRP inhibition. Therefore, until these multidrug transporter proteins are shown to have clear causative roles in drug resistance, we must question whether MRP inhibition will be a viable therapy in combination with traditional therapeutics.

References

1. Abe T, Mori T, Wakabayashi Y, Nakagawa M, Cole SP, Koike K, et al. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. *J Neurooncol.* 1998;40:11–8.
2. Ansari M, Sauty G, Labuda M, Gagne V, Laverdiere C, Moghrabi A, et al. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. *Blood.* 2009;114:1383–6.

3. Bagnoli M, Beretta GL, Gatti L, Pilotti S, Alberti P, Tarantino E, et al. Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma. *Biomed Res Int.* 2013;2013:143202.
4. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. *Mol Pharmacol.* 2000; 57:760–8.
5. Barnouin K, Leier I, Jedlitschky G, Pourtier-Manzanedo A, König J, Lehmann WD, et al. Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. *Br J Cancer.* 1998;77:201–9.
6. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell.* 2009;136:215–33.
7. Beck JF, Brugger D, Brischwein K, Liu C, Bader P, Niethammer D, et al. Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias. *Jpn J Cancer Res.* 2001;92:896–903.
8. Beesley J, Johnatty SE, Chen X, Spurdle AB, Peterlongo P, Barile M, et al. No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer risk in Caucasian women. *Breast Cancer Res Treat.* 2010;126:235–9.
9. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). *Cancer Res.* 2002;62:6172–7.
10. Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, Ling V, et al. Analysis of the in vivo functions of Mrp3. *Mol Pharmacol.* 2005;68:160–8.
11. Belinsky MG, Guo P, Lee K, Zhou F, Kotova E, Grinberg A, et al. Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. *Cancer Res.* 2007;67:262–8.
12. Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. *J Cancer Res Clin Oncol.* 2005;131:355–63.
13. Bessho Y, Oguri T, Ozasa H, Uemura T, Sakamoto H, Miyazaki M, et al. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. *Oncol Rep.* 2009;21:263–8.
14. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. *J Natl Cancer Inst.* 2000;92:1295–302.
15. Buchler M, König J, Brom M, Kartenbeck J, Spring H, Horie T, et al. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. *J Biol Chem.* 1996; 271:15091–8.
16. Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. *Ann Hematol.* 2010;89:1133–40.
17. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. *Clin Cancer Res.* 2003;9:827–36.
18. Burkhart CA, Watt F, Murray J, Pajic M, Prokvolit A, Xue C, et al. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. *Cancer Res.* 2009;69:6573–80.
19. Chan HS, Lu Y, Grogan TM, Haddad G, Hipfner DR, Cole SP, et al. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. *Cancer Res.* 1997;57:2325–30.
20. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. *J Biol Chem.* 2001;276:33747–54.

21. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD. Transport of bile acids, sulfated steroids, estradiol 17- β -D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). *Mol Pharmacol*. 2005;67:545–57.
22. Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. *J Pharmacol Exp Ther*. 1997;281:304–14.
23. Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. *J Pharmacol Exp Ther*. 1999;288:735–41.
24. Chu XY, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, et al. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). *J Pharmacol Exp Ther*. 2006;317:579–89.
25. Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. *Annu Rev Pharmacol Toxicol*. 2013;54:95–117.
26. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science*. 1992;258:1650–4.
27. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. *Cancer Res*. 1994;54:5902–10.
28. Conrad S, Kauffmann HM, Ito K, Deeley RG, Cole SP, Schrenk D. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. *J Hum Genet*. 2001;46:656–63.
29. Conseil G, Deeley RG, Cole SP. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. *Pharmacogenet Genomics*. 2005;15:523–33.
30. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial. *J Clin Oncol*. 2004;22:1234–41.
31. Cui Y, König J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. *Mol Pharmacol*. 1999;55:929–37.
32. de Wolf CJ, Yamaguchi H, van der Heijden I, Wielinga PR, Hundscheid SL, Ono N, et al. cGMP transport by vesicles from human and mouse erythrocytes. *Febs J*. 2007;274:439–50.
33. Dean M. The genetics of ATP-binding cassette transporters. *Methods Enzymol*. 2005;400:409–29.
34. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. *Nat Rev Cancer*. 2005;5:275–84.
35. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. *Physiol Rev*. 2006;86:849–99.
36. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res*. 2007;13:4429–34.
37. Dietrich CG, Ottenhoff R, de Waart DR, Oude Elferink RP. Role of MRP2 and GSH in intrahepatic cycling of toxins. *Toxicology*. 2001;167:73–81.
38. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. *Drug Metab Dispos*. 2010;38:1371–80.
39. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. *Breast Cancer Res*. 2007;9:R6.
40. El-Sharnouby JA, Abou El-Enein AM, El Ghannam DM, El-Shanshory MR, Hagag AA, Yahia S, et al. Expression of lung resistance protein and multidrug resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia. *J Oncol Pharm Pract*. 2009;16:179–88.

41. Endo K, Maehara Y, Ichiyoshi Y, Kusumoto T, Sakaguchi Y, Ohno S, et al. Multidrug resistance-associated protein expression in clinical gastric carcinoma. *Cancer*. 1996; 77:1681–7.
42. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, et al. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. *Br J Cancer*. 2000;83:375–83.
43. Filipits M, Suchomel RW, Zochbauer S, Brunner R, Lechner K, Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. *Clin Cancer Res*. 1997;3:1419–25.
44. Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, et al. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. *J Clin Oncol*. 2005;23:1161–8.
45. Filipits M, Haddad V, Schmid K, Huynh A, Dunant A, Andre F, et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: international adjuvant lung cancer trial biologic program. *Clin Cancer Res*. 2007;13:3892–8.
46. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJ, Scheper RJ, et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. *Cancer Res*. 1994;54:4557–63.
47. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. *Nat Rev Cancer*. 2010;10:147–56.
48. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. *Am J Pathol*. 2000;157:1575–80.
49. Furmanski BD, Hu S, Fujita K, Li L, Gibson AA, Janke LJ, et al. Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. *Clin Cancer Res*. 2013;19:4359–70.
50. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. *Nat Rev Drug Discov*. 2010;9:215–36.
51. Gorgels TG, Hu X, Scheffer GL, van der Wal AC, Toonstra J, de Jong PT, et al. Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum. *Hum Mol Genet*. 2005;14:1763–73.
52. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. *Cancer Res*. 1994;54:357–61.
53. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, et al. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. *J Biol Chem*. 2003;278:29509–14.
54. Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. *Eur J Cancer*. 2010;46:1692–702.
55. Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, London WB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. *J Clin Oncol*. 2006;24:1546–53.
56. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. *Curr Drug Metab*. 2004;5:21–53.
57. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. *Cancer Epidemiol Biomarkers Prev*. 2012;21:1848–55.
58. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. *Biochim Biophys Acta*. 2002;1587:318–25.

59. Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, et al. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. *J Natl Cancer Inst.* 2011;103:1236–51.
60. Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN. Regulation of prostaglandin transporters in colorectal neoplasia. *Cancer Prev Res (Phila Pa).* 2008;1:93–9.
61. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. *Cancer Res.* 1999;59:2532–5.
62. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. *Cancer Res.* 2004;64:4927–30.
63. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. *Cancer Res.* 2009;69:178–84.
64. Hopper-Borge EA, Churchill T, Paulose C, Nicolas E, Jacobs JD, Ngo O, et al. Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(–/–) mice. *Cancer Res.* 2011;71:3649–57.
65. Hsia TC, Lin CC, Wang JJ, Ho ST, Kao A. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. *Lung.* 2002;180:173–9.
66. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. *Clin Cancer Res.* 2009;15:6062–9.
67. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. *Int J Cancer.* 2005;116:824–9.
68. Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. *J Natl Cancer Inst.* 1995;87:1230–7.
69. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. *Cancer Res.* 1996;56:988–94.
70. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, Keppler D. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. *Biochem J.* 1997;327(Pt 1):305–10.
71. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. *J Biol Chem.* 2000;275:30069–74.
72. Kathawala RJ, Sodani K, Chen K, Patel A, Abuznait AH, Anreddy N, et al. Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study. *Mol Cancer Ther.* 2014;13:714–23.
73. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is over-expressed in hematopoietic stem cells. *Clin Cancer Res.* 2002;8:22–8.
74. Kim HS, Kim NC, Chae KH, Kim G, Park WS, Park YK, et al. Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma. *Biomed Res Int.* 2013;2013:527534.
75. Klappe K, Hinrichs JW, Kroesen BJ, Sietsma H, Kok JW. MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. *Int J Cancer.* 2004;110:511–22.
76. Klement JF, Matsuzaki Y, Jiang QJ, Terlizzi J, Choi HY, Fujimoto N, et al. Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. *Mol Cell Biol.* 2005;25:8299–310.
77. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. *Cancer Res.* 1997;57:5475–9.

78. Kok JW, Veldman RJ, Klappe K, Koning H, Filipeanu CM, Muller M. Differential expression of sphingolipids in MRP1 overexpressing HT29 cells. *Int J Cancer*. 2000;87:172–8.
79. Konig J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. *Hepatology*. 1999;29:1156–63.
80. Konig J, Hartel M, Nies AT, Martignoni ME, Guo J, Buchler MW, et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. *Int J Cancer*. 2005;115:359–67.
81. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. *Proc Natl Acad Sci U S A*. 1999;96:6914–9.
82. Koshiyama M, Yoshida M, Fujii H, Konishi M, Nanno H, Hayashi M, et al. Expression of multidrug resistance-associated protein in endometrial carcinomas: correlation with clinicopathology and prognosis. *Ann Diagn Pathol*. 1999;3:81–7.
83. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. *Mol Cancer Ther*. 2008;7:2152–9.
84. Kroetz DL, Yee SW, Giacomini KM. The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. *Clin Pharmacol Ther*. 2009;87:109–16.
85. Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. *Biochem Pharmacol*. 2010;79:154–61.
86. Lang T, Justenhoven C, Winter S, Baisch C, Hamann U, Harth V, et al. The earwax-associated SNP c.538G>A (G180R) in ABCC11 is not associated with breast cancer risk in Europeans. *Breast Cancer Res Treat*. 2011;129:993–9.
87. Larbcharoenub N, Leopairat J, Sirachainan E, Narkwong L, Bhongmakapat T, Rasmeepaisarn K, et al. Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy. *Hum Pathol*. 2008;39:837–45.
88. Leavy O. Therapeutic antibodies: past, present and future. *Nat Rev Immunol*. 2010;10:297.
89. Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. *J Natl Cancer Inst*. 2000;92:1934–40.
90. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. *Mol Cell Biol*. 2004;24:7612–21.
91. Legrand O, Zittoun R, Marie JP. Role of MRP1 in multidrug resistance in acute myeloid leukemia. *Leukemia*. 1999;13:578–84.
92. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. *J Biol Chem*. 1994;269:27807–10.
93. Leslie EM, Haimeur A, Waalkes MP. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. *J Biol Chem*. 2004;279:32700–8.
94. Letourneau IJ, Deeley RG, Cole SP. Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). *Pharmacogenet Genomics*. 2005;15:647–57.
95. Li XQ, Li J, Shi SB, Chen P, Yu LC, Bao QL. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. *Int J Biol Markers*. 2009;24:230–7.
96. Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB, et al. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. *Lung Cancer*. 2010;69:116–22.
97. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. *Biochem Pharmacol*. 2009;79:817–24.

98. Lin ZP, Zhu YL, Johnson DR, Rice KP, Nottoli T, Hains BC, et al. Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response. *Mol Pharmacol*. 2008;73:243–51.
99. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. *Cancer Res*. 1998;58:5130–6.
100. Lorico A, Rappa G, Finch RA, Yang D, Flavell RA, Sartorelli AC. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. *Cancer Res*. 1997;57:5238–42.
101. Maciejczyk A, Jagoda E, Wysocka T, Matkowski R, Gyorffy B, Lage H, et al. ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome. *Pathol Oncol Res*. 2011;18:331–42.
102. Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B. Transport function and hepatocellular localization of mrp6 in rat liver. *Mol Pharmacol*. 2000;57:634–41.
103. Montani M, Hermanns T, Muntener M, Wild P, Sulser T, Kristiansen G. Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression. *Virchows Arch*. 2013;462:437–43.
104. Morrow CS, Smitherman PK, Diah SK, Schneider E, Townsend AJ. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in anti-neoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. *J Biol Chem*. 1998;273:20114–20.
105. Morrow CS, Peklak-Scott C, Bishwokarma B, Kute TE, Smitherman PK, Townsend AJ. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. *Mol Pharmacol*. 2006;69:1499–505.
106. Naramoto H, Uematsu T, Uchihashi T, Doto R, Matsuura T, Usui Y, et al. Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. *Int J Oncol*. 2007;30:393–401.
107. Narvaiza I, Aparicio O, Vera M, Razquin N, Bortolanza S, Prieto J, et al. Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. *J Virol*. 2006;80:12236–47.
108. Nezasa K, Tian X, Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, Brouwer KL. Altered hepatobiliary disposition of 5 (and 6)-carboxy-2',7'-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. *Drug Metab Dispos*. 2006;34:718–23.
109. Nies AT, Jedlitschky G, Konig J, Herold-Mende C, Steiner HH, Schmitt HP, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. *Neuroscience*. 2004;129:349–60.
110. Nishimura Y, Mieda H, Ishii J, Ogino C, Fujiwara T, Kondo A. Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes. *J Nanobiotechnology*. 2013;11:19.
111. Nooter K, Burger H, Stoter G. Multidrug resistance-associated protein (MRP) in haematological malignancies. *Leuk Lymphoma*. 1996;20:381–7.
112. Nooter K, Kok T, Bosman FT, van Wingerden KE, Stoter G. Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy. *Eur J Cancer*. 1998;34:81–6.
113. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. *New Eng J Med*. 1996;334:231–8.
114. Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. *Mol Cancer Ther*. 2005;4:547–53.
115. O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, et al. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac,

- in combination with epirubicin in patients with advanced cancer. *Cancer Chemother Pharmacol.* 2007;59:79–87.
116. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. *J Clin Oncol.* 2006;24:5070–8.
 117. Oguri T, Ozasa H, Uemura T, Bessho Y, Miyazaki M, Maeno K, et al. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. *Mol Cancer Ther.* 2008;7:1150–5.
 118. Ono N, Van der Heijden I, Scheffer GL, Van de Wetering K, Van Deemter E, De Haas M, et al. Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm. *Biochem J.* 2007;406:31–40.
 119. Oshika Y, Nakamura M, Tokunaga T, Fukushima Y, Abe Y, Ozeki Y, et al. Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. *Mod Pathol.* 1998;11:1059–63.
 120. Ota I, Sakurai A, Toyoda Y, Morita S, Sasaki T, Chishima T, et al. Association between breast cancer risk and the wild-type allele of human ABC transporter ABCC11. *Anticancer Res.* 2010;30:5189–94.
 121. Pajic M, Murray J, Marshall GM, Cole SP, Norris MD, Haber M. ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript. *Pharmacogenet Genomics.* 2011;21:270–9.
 122. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. *Hepatology.* 1997;25:1539–42.
 123. Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. *J Clin Oncol.* 2001;19:3130–41.
 124. Plasschaert SL, de Bont ES, Boezen M, van der Kolk DM, Daenen SM, Faber KN, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. *Clin Cancer Res.* 2005;11:8661–8.
 125. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry 3rd W, Dantzig AH. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. *Mol Cancer Ther.* 2005;4:855–63.
 126. Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. *Biochem Biophys Res Commun.* 1998;247:859–63.
 127. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. *Proc Natl Acad Sci U S A.* 1999;96:3900–5.
 128. Rappa G, Lorico A, Flavell RA, Sartorelli AC. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. *Cancer Res.* 1997;57:5232–7.
 129. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. *Hepatology.* 2003;38:374–84.
 130. Robbiani DF, Finch RA, Jager D, Muller WA, Sartorelli AC, Randolph GJ. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. *Cell.* 2000;103:757–68.
 131. Roundhill E, Burchill S. Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT. *Br J Cancer.* 2013;109:195–206.
 132. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses

- multidrug resistance conferred by overexpression of both MDR1 and MRP. *J Clin Oncol.* 1998;16:2964–76.
133. Sakamoto H, Hara H, Hirano K, Adachi T. Enhancement of glucuronosyl etoposide transport by glutathione in multidrug resistance-associated protein-overexpressing cells. *Cancer Lett.* 1999;135:113–9.
 134. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. *Br J Haematol.* 2005;128:324–32.
 135. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. *Blood.* 2002;99:507–12.
 136. Schaub TP, Kartenbeck J, König J, Vogel O, Witzgall R, Kriz W, et al. Expression of the conjugate export pump encoded by the *mrp2* gene in the apical membrane of kidney proximal tubules. *J Am Soc Nephrol.* 1997;8:1213–21.
 137. Scheffer GL, Pijnenborg AC, Smit EF, Muller M, Postma DS, Timens W, et al. Multidrug resistance related molecules in human and murine lung. *J Clin Pathol.* 2002;55:332–9.
 138. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, et al. Tissue distribution and induction of human multidrug resistant protein 3. *Lab Invest.* 2002;82:193–201.
 139. Scheffer GL, Hu X, Pijnenborg AC, Wijnholds J, Bergen AA, Scheper RJ. MRP6 (ABCC6) detection in normal human tissues and tumors. *Lab Invest.* 2002;82:515–8.
 140. Semsei AF, Erdelyi DJ, Ungvari I, Csagoly E, Hegyi MZ, Kiszal PS, et al. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. *Cell Biol Int.* 2011;36:79–86.
 141. Shibayama Y, Nakano K, Maeda H, Taguchi M, Ikeda R, Sugawara M, et al. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. *Biol Pharm Bull.* 2011;34:433–5.
 142. Slot AJ, Molinski SV, Cole SP. Mammalian multidrug-resistance proteins (MRPs). *Essays Biochem.* 2011;50:179–207.
 143. Smitherman PK, Townsend AJ, Kute TE, Morrow CS. Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. *J Pharmacol Exp Ther.* 2004;308:260–7.
 144. Sosonkina N, Nakashima M, Ohta T, Niikawa N, Starenki D. Down-regulation of ABCC11 protein (MRP8) in human breast cancer. *Exp Oncol.* 2011;33:42–6.
 145. Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, Sauerbrey A. Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. *Clin Cancer Res.* 2003;9:1083–6.
 146. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, et al. Expression of members of the multidrug resistance protein family in human term placenta. *Am J Physiol Regul Integr Comp Physiol.* 2000;279:R1495–503.
 147. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SP, Deeley RG. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. *Mol Pharmacol.* 1997;52:344–53.
 148. Styczynski J, Wysocki M, Debski R, Czyzewski K, Kolodziej B, Rafinska B, et al. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. *J Cancer Res Clin Oncol.* 2007;133:875–93.
 149. Sugiyama D, Kusuhara H, Lee YJ, Sugiyama Y. Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-b-17beta-glucuronide (E217betaG) across the blood–brain barrier. *Pharm Res.* 2003;20:1394–400.
 150. Sumizawa T, Chuman Y, Sakamoto H, Iemura K, Almquist KC, Deeley RG, et al. Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein. *Somat Cell Mol Genet.* 1994;20:423–35.

151. Sun YL, Chen JJ, Kumar P, Chen K, Sodani K, Patel A, et al. Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. *PLoS One*. 2013;8:e55576.
152. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. *Nat Rev Drug Discov*. 2006;5:219–34.
153. Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). *Drug Discov Today*. 2008;13:379–93.
154. Tanaka M, Okazaki T, Suzuki H, Abbruzzese JL, Li D. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. *Cancer*. 2010;117:744–51.
155. Tao LY, Liang YJ, Wang F, Chen LM, Yan YY, Dai CL, et al. Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. *Cancer Chemother Pharmacol*. 2009;64:961–9.
156. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, et al. Human multidrug resistance associated protein 4 confers resistance to camptothecins. *Pharm Res*. 2005;22:1837–53.
157. Tribull TE, Bruner RH, Bain LJ. The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. *Toxicol Lett*. 2003;142:61–70.
158. Van Aubel RA, Koenderink JB, Peters JG, Van Os CH, Russel FG. Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. *Mol Pharmacol*. 1999;56:714–9.
159. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. *J Am Soc Nephrol*. 2002;13:595–603.
160. van Brussel JP, Mickisch GH. Multidrug resistance in prostate cancer. *Onkologie*. 2003;26:175–81.
161. Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, et al. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. *J Pharmacol Exp Ther*. 2006;318:319–27.
162. Vulsteke C, Lambrechts D, Dieudonne A, Hatse S, Brouwers B, van Brussel T, et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). *Ann Oncol*. 2013;24:1513–25.
163. Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. *J Invest Dermatol*. 2008;128:1925–9.
164. Weiss W, Aldape K, Mohapatra G, Feuerstein B, Bishop J. Targeted expression of MYCN causes neuroblastoma in transgenic mice. *EMBO Journal*. 1997;16:2985–95.
165. Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. *Cancer Res*. 2005;65:4425–30.
166. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. *Nat Med*. 1997;3:1275–9.
167. Wijnholds J, deLange EC, Scheffer GL, van den Berg DJ, Mol CA, van der Valk M, et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. *J Clin Invest*. 2000;105:279–85.
168. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. *Proc Natl Acad Sci U S A*. 2000;97:7476–81.
169. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. *Circulation*. 2005;112:3754–62.
170. Wu Z, Li X, Zeng Y, Zhuang X, Shen H, Zhu H, et al. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. *Basic Clin Pharmacol Toxicol*. 2010;108:177–84.

171. Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, Tanabe M, et al. High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. *Breast Cancer Res Treat.* 2013;137:773–82.
172. Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S, et al. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. *Br J Cancer.* 2011;104:707–13.
173. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). *J Biol Chem.* 2001;276:46400–7.
174. Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. *Proc Natl Acad Sci U S A.* 2005;102:7274–9.
175. Zeng H, Bain LJ, Belinsky MG, Kruh GD. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. *Cancer Res.* 1999;59:5964–7.
176. Zeng H, Liu G, Rea PA, Kruh GD. Transport of amphipathic anions by human multidrug resistance protein 3. *Cancer Res.* 2000;60:4779–84.
177. Zhang Y, Schuetz JD, Elmquist WF, Miller DW. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. *J Pharmacol Exp Ther.* 2004;311:449–55.
178. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. *Nat Med.* 2001;7:1028–34.

Resistance to Targeted ABC Transporters in Cancer

Efferth, Th. (Ed.)

2015, X, 300 p. 60 illus., 21 illus. in color., Hardcover

ISBN: 978-3-319-09800-5